Values First Advisors Inc. Has $857,000 Holdings in Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. cut its holdings in Guardant Health, Inc. (NASDAQ:GH) by 12.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 28,059 shares of the company’s stock after selling 3,966 shares during the quarter. Values First Advisors Inc.’s holdings in Guardant Health were worth $857,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after acquiring an additional 6,618,785 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after acquiring an additional 1,137,482 shares during the last quarter. ARK Investment Management LLC raised its holdings in Guardant Health by 233.5% during the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock worth $34,701,000 after acquiring an additional 1,059,104 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Guardant Health during the third quarter valued at approximately $21,389,000. Finally, Lord Abbett & CO. LLC bought a new position in Guardant Health in the third quarter valued at approximately $15,624,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 2,652 shares of company stock valued at $93,192 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partners reduced their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Sanford C. Bernstein reduced their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Guggenheim restated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. The Goldman Sachs Group raised their price objective on Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Sixteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $42.63.

Guardant Health Stock Down 1.8 %

GH stock opened at $43.60 on Wednesday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock’s 50 day simple moving average is $38.45 and its 200 day simple moving average is $30.81.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.